English
December 2005
Outwit investments completed the comprehensive tender offer and became the main shareholder of the company.
Company History
July 2008
Completion of very significant asset acquisition (VSA), acquisition of Yuanda Pharmaceutical (China) Co., Ltd. (formerly Wuhan Yuanda Pharmaceutical Group)
Complete the sale of very important assets, and sell the company’s original Apollo business and related assets.
August 2008
Changed of Company name to China Grand Pharmaceutical and Healthcare Holdings Ltd.
November 2008
Completed the acquisition with Wuhan Grand Hoyo
February 2010
Placed 200,000,000 new shares to renowned international and local institutional investors successfully and raised funds of approx. HK$ 90 million
May 2010
Completed the acquisition with Hubei Grand Everyday Bright Eyes Company Ltd.
June 2010
Complete the acquisition withHubei Grand Fuchi Pharmaceuticaland Chemical Co., Ltd.
October 2010
Completed the acquisition with Zhejiang Xianle
December 2010
Opened offer to quality shareholders at a subscription price of HK$ 0.58 per offer share on the basis of one offer share for every three existing shares held payable in full on application, and thus raised funds of HK$ 278 million
September 2011
Completed discloseable transaction, acquisition of equity interest in Wuhan Kernel Bio Tech Co.,Ltd.
February 2012
Through Acquisition, the Company current owned 75.95% of the Grand Pharm (China) Company Limited.
September 2012
Formation of Hubei Grand Bio-technology Limited
November 2012
Completion of acquisition with Hubei Wellness Pharmaceutical Company Limited
December 2012
The Company held up to 99.6% equity interests of Grand Pharm (China)
February 2013
Formation of a Joint Venture Company with Huangshi Feiyun Pharmaceutical Company Limited
July 2013
Entered into an acquisitionagreement, acquired 70.84% equity interests of Beijing Rui Yao
October 2014
Increased in the registered capital of Grand Pharm (China) to hold 99.84%
December 2014
Acquired 100% equity interests of Tianjin Jingming
April 2015
Acquired 73% equity interests of German based company Cardionovum GmbH with CDB-Equipment Manufacturing Investment Fund Co., Ltd., and set up a PRC Joint Venture company
July 2015
Acquired 67% equity interests of Beijing Grand Jiu He
November 2015
Acquired another 30% equity interest of Beijing Grand Jiu He, and held 97% of the entire equity interests of Beijing Grand Jiu He
June 2016
Acquired 77.2133% equity interests of Xian Beilin Pharmaceutical Company Limited
November 2017
Acquired shares of a medical devices company in Canada – Conavi Medical Inc. and established a joint venture company
May 2018
Acquired 55% equity interests of Shanghai Xudong Haipu Co., Limited
September 2018
Established joint venture with CDH Genetech Co., Limited to acquire Sirtex Medical Co., Limited, the Group occupied 49% of shareholding to Sirtex
February 2019
Entered into an exclusive license agreement with Swiss-based R&D company Glenmark Specialty S.A., thereby the Group being licensed to exclusively sell Ryaltrisin China for a period of 20 years
October 2019
Purchased 44% shares of OncoSec Medical Incorporated, a clinical-stage biotechnology company
November 2019
Entered into an exclusive licensing and co-development agreement with Griffith University in Australia, pursuant to which the Group obtained the global development and commercialization rights for the world-wide first developed product for the treatment of parainfluenza infection
December 2019
Entered into a tripartite intellectual property licensing agreement and related R&D project assignment with Sirtex and Australian National University, concerning the HIP project for the treatment of sepsis
December 2019
Entered into a licensing agreement and will subscribe certain shares of BRIM Biotechnology, Inc.
March 2020
Entered into a technology transfer agreement with Chongqing AnTi New Bio-technology Limited and obtained all rights of technical and intellectual property around the world for the world-wide first developed drug APAD
April 2020
Entered into a product licensing agreement with Cloudbreak Bio-Pharmaceutical Science and Technology (Guangzhou) Co., Ltd. and CloudBreak Therapeutics LLC, and acquired approximately 6.5% interest of the enlarged share capital of Cloudbreak Pharmaceutical Inc.
May 2020
Entered into an investment agreement with a Belgium company eTheRNA Immunotherapies NV and will obtain its 12% Preferred Series B Shares. Also agreed certain terms with eTheRNA for strategic cooperation and subject to further negotiation, including the exclusive development and commercialization rights in Greater China of its R&D projects
June 2020
Invested in CNCB Grand Pham Healthcare Fund , with the proposed capital commitment of the Group amounted to US$50 million. The Fund intends to raise a total of US$200 million, for investing in the world’s leading pharmaceutical companies and medical device manufacturers
July 2020
The Group entered into an equity investment agreement with with Shanghai Revolmmune Therapeutics Biotechnology Limited, pursuant to which the Group will invest RMB30,000,000 into Revolmmune to obtain approximately 9.7% equity interests, and obtain the exclusive global rights for the innovative product VSV-GPM for the treatment of colorectal cancer, and also the pre-emptive rights of cooperation for other products developed by Revolmmune
July 2020
The Group shall invest in the third-generation stent retriever and its ancillary products for the treatment of cerebral stroke, and contribute RMB 51,000,000 to the Nanjing Fund to invest in future projects relating to healthcare, pharmaceutical and medical devices, etc.